Team:TU Delft/12 July 2010 content

From 2010.igem.org

(Difference between revisions)
(Characterization of Anderson RBS sequences)
 
(8 intermediate revisions not shown)
Line 1: Line 1:
-
==Lab work==
+
=Lab work=
-
<h4>Characterization of Anderson RBS sequences</h4>
+
==Characterization of Anderson RBS sequences==
-
''E.coli'' Top10 strains containing the following composite BioBricks in pSB1A2 [https://2010.igem.org/Team:TU_Delft#/blog?blog=8_July_2010 had been obtained]:
+
''E.coli'' Top10 strains containing the following composite BioBricks in pSB1A2 [https://2010.igem.org/Team:TU_Delft#page=pages/blog&blog=8_July_2010 had been obtained]:
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
Line 24: Line 24:
|}
|}
-
To prepare for the fluorescence assay measurements the strains were grown in M9 minimal medium containing 0.4% glucose and 100 μg/mL Ampicillin.  
+
To prepare for the fluorescence assay measurements the strains were grown in 3 mL LB medium containing 100 μg/mL AMP as well as in M9 minimal medium containing 0.4% glucose and 100 μg/mL AMP.
High copy number RBS characterizations are rarely indicative of RiPS in system operation plasmids, thus we are planning to also measure the fluorescence assays with the BioBricks on pSB3C5. In order to obtain sufficient BioBrick DNA the strains were grown in 250 mL LB with 100 μg/mL Ampicillin, awaiting plasmid isolation and plasmid swapping.
High copy number RBS characterizations are rarely indicative of RiPS in system operation plasmids, thus we are planning to also measure the fluorescence assays with the BioBricks on pSB3C5. In order to obtain sufficient BioBrick DNA the strains were grown in 250 mL LB with 100 μg/mL Ampicillin, awaiting plasmid isolation and plasmid swapping.
-
<h4>Emulsifier</h4>
+
==Emulsifier==
The bricks for emulsifier production were assembled. The stock plasmids containing AlnA, OprG, R0011 and B0032 were digested and ligated into plasmid pSB1T3.
The bricks for emulsifier production were assembled. The stock plasmids containing AlnA, OprG, R0011 and B0032 were digested and ligated into plasmid pSB1T3.
Line 34: Line 34:
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
|'''#'''
|'''#'''
-
|'''Digestion reaction'''
+
|'''Sample'''
-
|'''Used Buffer'''
+
|'''Enzyme 1'''
 +
|'''Enzyme 2'''
 +
|'''Buffer'''
 +
|'''BSA'''
|'''Needed fragment'''
|'''Needed fragment'''
|-
|-
|1
|1
-
|1,0 μg AlnA + EcoRI + SpeI
+
|1.0 μg AlnA
-
|Buffer 2 + BSA
+
|EcoRI
-
|‘E – AlnA – S’
+
|SpeI
 +
|2 (BioLabs)
 +
|
 +
|‘E–AlnA–S’
|-
|-
|2
|2
-
|1,0 μg OprG + EcoRI + SpeI
+
|1.0 μg OprG
-
|Buffer 2 + BSA
+
|EcoRI
-
|‘E – OprG – S’
+
|SpeI
 +
|2 (BioLabs)
 +
|
 +
|‘E–OprG–S’
|-
|-
|3
|3
-
|1,0 μg R0011 + EcoRI + SpeI
+
|1.0 μg R0011
-
|Buffer 2 + BSA
+
|EcoRI
-
|‘E – R0011 – S’
+
|SpeI
 +
|2 (BioLabs)
 +
|
 +
|‘E–R0011–S’
|-
|-
|4
|4
-
|1,0 μg B0032 + XbaI + PstI
+
|1.0 μg B0032
-
|Buffer 2 + BSA
+
|XbaI
-
|‘X – B0032 – P’
+
|PstI
 +
|2 (BioLabs)
 +
|
 +
|‘X–B0032–P’
|-
|-
|5
|5
-
|1,0 μg B0015 + XbaI + PstI
+
|1.0 μg B0015
-
|Buffer 2 + BSA
+
|XbaI
-
|‘X – B0015 – P’
+
|PstI
 +
|2 (BioLabs)
 +
|
 +
|‘X–B0015–P’
|-
|-
|6
|6
-
|1,0 μg pSB1T3 + EcoRI + PstI
+
|1.0 μg pSB1T3
-
|Buffer 2 + BSA
+
|EcoRI
-
|‘E – ---- – P’
+
|PstI
 +
|2 (BioLabs)
 +
|✓
 +
|‘E–linear pSB1T3–P’
|}
|}
Line 73: Line 94:
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
{| style="color:black; background-color:white;" cellpadding="5" cellspacing="0" border="1"
|'''#'''
|'''#'''
-
|'''Ligation reaction'''
+
|'''BioBrick'''
 +
|'''Fragment 1'''
 +
|'''Fragment 2'''
 +
|'''Recipient vector'''  
|-
|-
|1
|1
-
|μL R0011 + μL B0032 + μL pSB1T3
+
|K398202
 +
|μL ‘E–R0011–S’
 +
|μL ‘X–B0032–P’
 +
|μL ‘E–linear pSB1T3–P’
|-
|-
|2
|2
-
|μL AlnA + μL B0015 + μL pSB1T3
+
|K398203
 +
|μL ‘E–AlnA–S’
 +
|μL ‘X–B0015–P’
 +
|μL ‘E–linear pSB1T3–P’
|-
|-
|3
|3
-
|μL OprG + μL B0015 + μL pSB1T3
+
|K398204
 +
|μL ‘E–OprG–S’
 +
|μL ‘X–B0015–P’
 +
|μL ‘E–linear pSB1T3–P’
|-
|-
|4
|4
-
|μL pSB3C5 (negative control)
+
|negative control
 +
|'''-'''
 +
|'''-'''
 +
|μL ‘E–linear pSB1T3–P’
|}
|}

Latest revision as of 12:38, 3 August 2010

Lab work

Characterization of Anderson RBS sequences

E.coli Top10 strains containing the following composite BioBricks in pSB1A2 had been obtained:

BioBrick Composed of:
K398500 J23100 + J61100 + I13401
K398501 J23100 + J61101 + I13401
K398502 J23100 + J61107 + I13401
K398503 J23100 + J61117 + I13401
K398504 J23100 + J61127 + I13401

To prepare for the fluorescence assay measurements the strains were grown in 3 mL LB medium containing 100 μg/mL AMP as well as in M9 minimal medium containing 0.4% glucose and 100 μg/mL AMP.

High copy number RBS characterizations are rarely indicative of RiPS in system operation plasmids, thus we are planning to also measure the fluorescence assays with the BioBricks on pSB3C5. In order to obtain sufficient BioBrick DNA the strains were grown in 250 mL LB with 100 μg/mL Ampicillin, awaiting plasmid isolation and plasmid swapping.

Emulsifier

The bricks for emulsifier production were assembled. The stock plasmids containing AlnA, OprG, R0011 and B0032 were digested and ligated into plasmid pSB1T3.

Digested were performed according to the digestion protocol:

# Sample Enzyme 1 Enzyme 2 Buffer BSA Needed fragment
1 1.0 μg AlnA EcoRI SpeI 2 (BioLabs) ‘E–AlnA–S’
2 1.0 μg OprG EcoRI SpeI 2 (BioLabs) ‘E–OprG–S’
3 1.0 μg R0011 EcoRI SpeI 2 (BioLabs) ‘E–R0011–S’
4 1.0 μg B0032 XbaI PstI 2 (BioLabs) ‘X–B0032–P’
5 1.0 μg B0015 XbaI PstI 2 (BioLabs) ‘X–B0015–P’
6 1.0 μg pSB1T3 EcoRI PstI 2 (BioLabs) ‘E–linear pSB1T3–P’

The digestion products were ligated overnight:

# BioBrick Fragment 1 Fragment 2 Recipient vector
1 K398202 μL ‘E–R0011–S’ μL ‘X–B0032–P’ μL ‘E–linear pSB1T3–P’
2 K398203 μL ‘E–AlnA–S’ μL ‘X–B0015–P’ μL ‘E–linear pSB1T3–P’
3 K398204 μL ‘E–OprG–S’ μL ‘X–B0015–P’ μL ‘E–linear pSB1T3–P’
4 negative control - - μL ‘E–linear pSB1T3–P’